Patents by Inventor Gabriella Colucci

Gabriella Colucci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220088100
    Abstract: The present invention refers to the cosmetic, pharmaceutical, nutraceutical use of an extract derived from cell cultures of Cannabis sativa, preferably a hydro-alcoholic extract, and a cosmetic, pharmaceutical, nutraceutical composition comprising this extract; in particular, the composition containing this extract of Cannabis sativa may be used to reduce neurogenic inflammation and stimulate the production of neurotransmitters or neuropeptides, such as dopamine and endorphin.
    Type: Application
    Filed: December 16, 2019
    Publication date: March 24, 2022
    Applicant: ARTERRA BIOSCIENCE S.P.A.
    Inventors: Marida Bimonte, Assunta Tortora, Fabio Apone, Maria Gabriella Colucci
  • Publication number: 20210308038
    Abstract: The present invention relates to a composition with an antioxidant activity, comprising a first dry extract derived from plant cell cultures comprising superoxide dismutase of Sulfolobus solfataricus, a second dry extract derived from plant cell cultures comprising superoxide dismutase of Aeropyrum pernix and a third dry extract derived from plant cell cultures comprising superoxide dismutase from Deinococcus radiodurans, wherein said plant cell cultures are cultures of cells belonging to Solanum lycopersicum species.
    Type: Application
    Filed: August 28, 2019
    Publication date: October 7, 2021
    Applicant: ARTERRA BIOSCIENCE S.P.A.
    Inventors: Stefania Arciello, Fabio Apone, Maria Gabriella Colucci, Gianna Palmieri, Ennio Cocca
  • Patent number: 11045670
    Abstract: The present invention refers to a method for obtaining plant cell cultures, enriched of somatic embryos, a method of preparation of the extracts derived from these cell cultures, and the use of the obtained extracts in cosmetic compositions, targeted to treat imperfections related to skin aging and for inducing a skin tissue rejuvenation effect.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: June 29, 2021
    Assignee: VITALAB S.R.L.
    Inventors: Annalisa Tito, Ani Barbulova, Marida Bimonte, Fabio Apone, Gabriella Colucci
  • Publication number: 20180303749
    Abstract: The present invention refers to a method for obtaining plant cell cultures, enriched of somatic embryos, a method of preparation of the extracts derived from these cell cultures, and the use of the obtained extracts in cosmetic compositions, targeted to treat imperfections related to skin aging and for inducing a skin tissue rejuvenation effect.
    Type: Application
    Filed: April 18, 2016
    Publication date: October 25, 2018
    Applicant: VITALAB S.R.L.
    Inventors: Annalisa Tito, Ani Barbulova, Marida Bimonte, Fabio Apone, Gabriella Colucci
  • Publication number: 20130011372
    Abstract: The present invention relates to a new group of pesticides consisting of inactivated microorganisms containing double-strand RNA molecules (dsRNA), corresponding to receptor genes coupled with G proteins (GPCR) whose functioning is vital for phytophagous invertebrates (insects, mites and molluscs) or for infesting or in any case harmful organisms for the health of human beings and domestic animals, and to a method for the preparation of said microorganisms.
    Type: Application
    Filed: September 17, 2010
    Publication date: January 10, 2013
    Applicant: ARTERRA BIOSCIENCE S.R.L
    Inventors: Assunta Tortora, Maria Rosaria Grimaldi, Alessandra Ruggiero, Lucio Filippini, Fabio Apone, Maria Gabriella Colucci
  • Patent number: 8349770
    Abstract: The present invention relates to a method for the preparation of 4-hyroxy-L-proline or compositions with a high content of this aminoacid and the use thereof as agrochemical in the agronomical field and/or as a synthesis intermediate of chemical compounds.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: January 8, 2013
    Assignee: Arterra Bioscience S.R.L.
    Inventors: Maria Gabriella Colucci, Fabio Apone, Maarten J Chrispeels
  • Publication number: 20110150839
    Abstract: The present invention relates to a method to obtain transgenic plants resistant to the attack of phytopathogens (i.e. parasites and phytophages) based on RNA interference, which contemplates the expression of double strand RNA (dsRNA) in the plant tissues, suitable for inhibiting the functionality of a GPCR receptor, whose functioning is vital for fungi, herbivorous insects or phytopathogenic nematodes.
    Type: Application
    Filed: July 15, 2009
    Publication date: June 23, 2011
    Applicant: ARTERRA BIOSCIENCE S.R.L.
    Inventors: Stefania Arciello, Davide Andrenacci, Fabio Napoli, Maria Gabriella Colucci
  • Publication number: 20090105238
    Abstract: Amphoteric compounds are described, having a zwitterionic structure of the betainic type having general formula (I) and their use for the control of phytopathogen fungi and/or the mitigation of abiotic and biotic stress.
    Type: Application
    Filed: October 10, 2006
    Publication date: April 23, 2009
    Applicant: ISAGRO RICERCA S.r.l
    Inventors: Lucio Filippini, Marilena Gusmeroli, Silvia Mormile, Gregorio Valea, Luigi Mirenna, Maria Gabriella Colucci, Fabio Apone
  • Publication number: 20090054241
    Abstract: The present invention relates to a method for the preparation of 4-hyroxy-L-proline or compositions with a high content of this aminoacid and the use thereof as agrochemical in the agronomical field and/or as a synthesis intermediate of chemical compounds.
    Type: Application
    Filed: March 6, 2007
    Publication date: February 26, 2009
    Inventors: Maria Gabriella Colucci, Fabio Apone, Maarten J. Chrispeels
  • Patent number: 6991794
    Abstract: Disclosed are the FRIL family of progenitor cell preservation factors and nucleic acids encoding the same. FRIL family members preserve progenitor cells both in vivo and ex vivo. FRIL family members find use as therapeutics for alleviating and/or reducing the hematopoietic progenitor cell-depleting activity of many cancer therapeutics. FRIL family members are also useful for isolating rare, primitive progenitor cells.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: January 31, 2006
    Assignees: ImClone Systems Incorporated, The Regents of the University of California
    Inventors: M. Gabriella Colucci, Maarten J. Chrispeels, Jeffrey G. Moore
  • Patent number: 6852321
    Abstract: The invention relates to an isolated nucleic acid molecule that encodes a protein that is effective to preserve progenitor cells, such as hematopoietic progenitor cells. The nucleic acid comprises a sequence defined by SEQ ID NO:1, a homolog thereof, or a fragment thereof. The encoded protein has an amino acid sequence that comprises a sequence defined by SEQ ID NO:2, a homolog thereof or a fragment thereof that contains an amino acid sequence TNNVLQVT. Methods of using the encoded protein for preserving progenitor cells in vitro, ex vivo, and in vivo are also described. The invention, therefore, include methods such as myeloablation therapies for cancer treatment wherein myeloid reconstitution is facilitated by means of the specified protein.
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: February 8, 2005
    Assignees: ImClone Systems Incorporated, Regents of the University of California
    Inventors: M. Gabriella Colucci, Maarten J. Chrispeels, Jeffrey G. Moore
  • Publication number: 20030073812
    Abstract: The invention relates to transmembrane receptors for which the endogenous ligand has not been identified, and specifically to a plant GPCR (“GCR1”) that has been altered to establish constitutive activity of the receptor. In some embodiments, the altered versions of GCR1 are used for the direct identification of candidate compounds as receptor agonists, inverse agonists or partial agonists for use in, for example and not limitation, herbicidal relevance; germination; growth elongation; seed dormancy; and fruit and vegetable ripening and development. In some embodiments, altered versions of GCR1 are used to modulate physiological processes in a plant. The invention further relates to plants comprising constitutively activated non-endogenous GPCRs.
    Type: Application
    Filed: June 5, 2002
    Publication date: April 17, 2003
    Inventor: Gabriella Colucci
  • Publication number: 20030049339
    Abstract: The invention relates to an isolated nucleic acid molecule that encodes a protein that is effective to preserve progenitor cells, such as hematopoietic progenitor cells. The nucleic acid comprises a sequence defined by SEQ ID NO:1, a homolog thereof, or a fragment thereof. The encoded protein has an amino acid sequence that comprises a sequence defined by SEQ ID NO:2, a homolog thereof or a fragment thereof that contains an amino acid sequence TNNVLQVT. Methods of using the encoded protein for preserving progenitor cells in vitro, ex vivo, and in vivo are also described. The invention, therefore, include methods such as myeloablation therapies for cancer treatment wherein myeloid reconstitution is facilitated by means of the specified protein.
    Type: Application
    Filed: October 29, 2001
    Publication date: March 13, 2003
    Applicant: Regents of the University of California
    Inventors: M. Gabriella Colucci, Maarten J. Chrispeels, Jeffrey G. Moore
  • Patent number: 6310195
    Abstract: The invention relates to an isolated nucleic acid molecule that encodes a protein that is effective to preserve progenitor cells, such as hematopoietic progenitor cells. The nucleic acid comprises a sequence defined by SEQ ID NO:1, a homolog thereof, or a fragment thereof. The encoded protein has an amino acid sequence that comprises a sequence defined by SEQ ID NO:2, a homolog thereof, or a fragment thereof that contains an amino acid sequence TNNVLQVT. Methods of using the encoded protein for preserving progenitor cells in vitro, ex vivo, and in vivo are also described. The invention, therefore, include methods such as myeloablation therapies for cancer treatment wherein myeloid reconstitution is facilitated by means of the specified protein.
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: October 30, 2001
    Assignee: ImClone Systems Incorporated
    Inventors: M. Gabriella Colucci, Maarten J. Chrispeels, Jeffrey G. Moore